Last reviewed · How we verify

Eligard (TM)

Chesapeake Urology Research Associates · FDA-approved active Small molecule

Eligard is a leuprolide acetate depot injection that suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to reduced testosterone production.

Eligard is a leuprolide acetate depot injection that suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to reduced testosterone production. Used for Advanced prostate cancer, Prostate cancer requiring androgen deprivation therapy.

At a glance

Generic nameEligard (TM)
SponsorChesapeake Urology Research Associates
Drug classGnRH agonist
TargetGnRH receptor
ModalitySmall molecule
Therapeutic areaOncology
PhaseFDA-approved

Mechanism of action

Leuprolide is a gonadotropin-releasing hormone (GnRH) agonist that initially stimulates the pituitary gland but with continuous exposure causes downregulation of GnRH receptors, resulting in sustained suppression of gonadal hormone secretion. This leads to castration-level testosterone suppression, which is the therapeutic goal in hormone-sensitive prostate cancer. Eligard is a sustained-release formulation designed to provide continuous drug delivery over weeks to months.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: